Multicenter, Single-Blinded, Randomized, Comparator-Controlled Noninferiority Trial to Compare the Efficacy & Safety of Resusix With FP24 in Patients With Acquired Coagulopathy
Phase of Trial: Phase II
Latest Information Update: 03 Oct 2019
Price : $35 *
At a glance
- Drugs Plasma (Primary)
- Indications Blood coagulation disorders
- Focus Adverse reactions; Therapeutic Use
- Sponsors Entegrion
- 30 Sep 2019 Planned End Date changed from 30 Nov 2020 to 30 Jun 2021.
- 30 Sep 2019 Planned primary completion date changed from 30 Apr 2020 to 31 Dec 2020.
- 31 Dec 2018 Status changed from not yet recruiting to recruiting.